(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(2009) 51st Annual Meeting of the American-Society-of-Hematology In Blood 114(22). p.384-384
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1616252
- author
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 114
- issue
- 22
- pages
- 384 - 384
- publisher
- American Society of Hematology
- conference name
- 51st Annual Meeting of the American-Society-of-Hematology
- conference dates
- 2009-12-05 - 2009-12-08
- external identifiers
-
- wos:000272725801112
- ISSN
- 1528-0020
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)
- id
- 31dcaf48-96ac-428a-ac07-7e713431f93f (old id 1616252)
- date added to LUP
- 2016-04-01 11:51:05
- date last changed
- 2018-11-21 20:00:57
@misc{31dcaf48-96ac-428a-ac07-7e713431f93f, author = {{Kolstad, Arne and Laurell, Anna and Andersen, Niels S. and Elonen, Erkki and Raty, Riikka and Pedersen, Lone Bredo and Loft, Annika and Bogsrud, Trond Velde and Nordstrom, Marie and Gillstrom, Dorte and Hansen, Per Boye and Bentzen, Hans and Fagerli, Unn-Merete and Meyer, Peter and Nilsson-Ehle, Herman and Jerkeman, Mats and Lehmann, Anne Kristine and Lauritzsen, Grete F. and Sundstrom, Christer and Delabie, Jan and Karjalainen-Lindsberg, Marja-Liisa and Ralfkiaer, Elisabeth and Ehinger, Mats and Geisler, Christian H.}}, issn = {{1528-0020}}, language = {{eng}}, note = {{Conference Abstract}}, number = {{22}}, pages = {{384--384}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)}}, volume = {{114}}, year = {{2009}}, }